All posts by imreal

Mount Sinai Study Identifies New Gene That Drives Colon Cancer


“This cancer is reliant on surgery for treatment, and immunotherapies that have revolutionized the treatment of advanced cancer have only worked for a small subset of colon cancer patients,” said study author Royce Zhou. “That’s why there’s a great need for novel target identification.”

Researchers at Mount Sinai’s Tisch Cancer Institute have identified a new gene that is essential to colon cancer growth and found that inflammation in the external environment around the tumor can contribute to the growth of tumor cell s. The scientists reported these findings in Nature Communications in October.

This is the first time that scientists have discovered that the environment around a colon cancer tumor can program what is known as a “super enhancer,” a complex area of DNA with a high concentration of transcriptional machinery that controls whether a cell is malignant.

This super enhancer — the largest 1-2% of all enhancers in the cell– regulates the gene PDZK1IP1, which was previously not identified as a cancer gene. Once researchers deleted PDZK1IP1, colon cancer growth slowed down, suggesting that PDZK1IP1 and its super enhancer could be targets for anti-cancer therapies.

“In the United States, colon cancer is the third most prevalent and second most deadly cancer,” said the study’s first author Royce Zhou, an MD/PhD student at the Icahn School of Medicine at Mount Sinai. “This cancer is reliant on surgery for treatment, and immunotherapies that have revolutionized the treatment of advanced cancer have only worked for a small subset of colon cancer patients. That’s why there’s a great need for novel target identification.”

This study found that the super enhancer – the largest 1-2% of all enhancers in the cell – is activated by surrounding inflammation in the tumor microenvironment. The inflammation allows the cancer cells to survive in an environment they otherwise would not. Inflammatory bowel disease is a known risk for colon cancer; this finding could add to the understanding of the mechanism involved.

“What this means for most patients with colon cancer is that inflammation that’s occurring in the tumor is contributing to the tumor’s growth. This stresses the importance of understanding what we can do to curb the inflammatory effects in the colon through prevention or understanding what dietary effects might have on the microenvironment in the colon,” said senior author Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “In terms of treatment, we have genetic evidence that targeting this gene actually inhibits tumors. By understanding all these different components, we will have better tools to try to prevent the disease.”

“This discovery was made possible by studying live tumor tissue and surrounding healthy tissue immediately after the surgeries of 15 colon cancer patients. Being able to prepare and analyze live cells allowed researchers to see the tumor microenvironment and the genetic and biologic drivers of colon cancer,” Mr. Zhou said.

“We had live specimen live cells straight from the operating room that allowed us to immediately measure the epigenetic state of that tumor,” Dr. Parsons added. “Without that infrastructure here at Mount Sinai, we couldn’t have made this discovery.”

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

Nose Specialist Dr. Jeffrey Lisiecki Joins Exclusive Haute Beauty Network


News Image

He takes a personalized approach to plastic surgery, helping patients achieve beautiful results aligned with their anatomy and goals.

Dr. Jeffrey Lisiecki is a fellowship-trained aesthetic plastic surgeon in New York City specializing in highly personalized procedures tailored to each individual’s anatomy and goals. A Michigan native, he graduated magna cum laude from Brown University and then graduated with distinction from the University of Michigan Medical School. He completed a six-year Plastic and Reconstructive Surgery residency program at the University of Michigan, where he was the chief resident in his final year of residency training. He completed the highly prestigious aesthetic surgery fellowship at Dallas Plastic Surgery Institute, under the world-renowned rhinoplasty and facelift specialist Dr. Rod Rohrich and other experts in the field. He is the author of numerous papers and textbook chapters, and has received awards for his teaching, patient care, and research, particularly in the field of rhinoplasty. He has taught national courses on facial anatomy and techniques for injectables and surgery.

At his Park Avenue plastic surgery office, Dr. Lisiecki listens closely to patients and their concerns before discussing their best treatment options and making plans. He takes a personalized approach to plastic surgery, helping patients achieve beautiful results aligned with their anatomy and goals. He conducts his practice with the highest level of care, open communication, and diligence. He believes in maintaining open communication channels with his patients at every stage of the surgical and recovery process. During consultations, he walks you through all of your surgical and non-surgical options and only recommends procedures that align with your expectations and goals. Dr. Lisiecki delivers all treatments with warmth and compassion.

Dr. Lisiecki maintains admitting and operating privileges at Lenox Hill Hospital and its affiliate, the Manhattan Eye, Ear & Throat Hospital.

Learn more about Dr. Jeffrey Lisiecki by visiting: https://hauteliving.com/hautebeauty/member/dr-jeffrey-lisiecki/

ABOUT HAUTE BEAUTY NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/

Share article on social media or email:

The DEO (Dentist Entrepreneur Organization) Announces DEO Partner Ken Kaufman’s New Position as President of Nuvia Dental Implant Center


The Dentist Entrepreneur Organization (The DEO) of Austin, Texas, is pleased to announce that DEO Partner, Ken Kaufman has accepted a position as President & CFO of Nuvia Dental Implant Center, headquartered in Cottonwood Heights, Utah.

Previously, Kaufman was CFO of Community Dental Partners of Denton, Texas.

As a DEO Partner, Kaufman offers DSO industry expertise as an advisor to DEO programs and members. He regularly speaks at private DEO member events and the yearly DEO Growth Summit. Kaufman frequently hosts DSO finance and growth topic-related episodes of the DSO Secrets Podcast, a podcast produced by DEO.

“We are very fortunate to have Ken as a DEO Partner. He generously shares his extensive knowledge of the DSO industry, leadership, and the day-to-day experience of leading a dental organization with our members. We congratulate him on his new role with Nuvia Dental Implant Center and look forward to celebrating his success,” said Jacob Puhl, CEO of the DEO.

Kaufman is a sought-after speaker and thought leader in the dental industry and founded DEO’s free Dental Finance Forum mastermind, the first of its kind that exclusively supports finance leaders of group practices and DSOs. He is also authoring a book, “DEO’s Financial Secrets To Grow Dental Organizations: The 9 Required Clarity Tools”, published by DEO Media, LLC, scheduled to be released by the end of this year..

Kaufman earned a business degree from BYU and an MBA from the University of Georgia in finance and entrepreneurship. Since 2004, Kaufman has served in CFO and President/CFO roles in venture capital and private equity-backed high-growth organizations, helping to drive the growth of 3 to 10x during his tenure at each.

He started his journey in dental finance in 2006. Previously, he was the President/CFO of the NOMAD handheld X-ray business until the business was sold to the KavoKerr Group. Kaufman served as CFO of Community Dental Partners for 6 years, and helped it expand from 7 practices to 70+ to date.

Kaufman has received many accolades throughout his career, such as being awarded Utah Business Magazine’s CFO of the year, making their top 40 under 40, and being named V100 entrepreneur by Signal Peak Ventures. He is also the creator of and host of the successful podcast, Net Worth Hacks.

Despite his many achievements, he still gets an enormous kick out of the role he plays in supporting clinicians as they build a new practice, welcome their first patients, and start making a real difference in their community.

The DEO is looking forward to leveraging Ken’s knowledge as he grows in his new role, to help DEO members and followers on their path to success.

About

The Dentist Entrepreneur Organization© (DEO) supports dental entrepreneurs and executives who see a future bigger than they can achieve alone by giving them the education, resources, and connections they need to grow their dental groups and fulfill their vision.

For more information, visit https://deodentalgroup.com/.

Share article on social media or email:

Highmark Health/AHN Chief Clinical Diversity, Equity and Inclusion Officer Margaret Larkins-Pettigrew, MD, again named national Top Diversity Leader by Modern Healthcare


Dr. Larkins-Pettigrew (MEd, MPPM, FACOG),Senior Vice President and Chief Diversity, Equity and Inclusion Officer for Highmark Health and Allegheny Health Network (AHN).

“The honorees’ efforts to provide greater opportunities internally while advancing health equity initiatives in their communities set a great example for others to follow.” Mary Ellen Podmolik, Modern Healthcare,

For the second year in a row, Pittsburgh’s Margaret Larkins-Pettigrew, MD, has been selected by Modern Healthcare magazine as one of the industry’s Top Diversity Leaders.

Dr. Larkins-Pettigrew (MEd, MPPM, FACOG) is the Senior Vice President and Chief Diversity, Equity and Inclusion Officer for Highmark Health and Allegheny Health Network (AHN). A practicing obstetrician and gynecologist, Dr. Larkins-Pettigrew has spent her career engaging marginalized communities and building programs that promote access and outcomes equity for vulnerable patients and mitigate socio-economic barriers to care, particularly for women. She also is a Professor of Obstetrics and Gynecology at Drexel University School of Medicine.

Modern Healthcare’s annual “Top Diversity Leaders” recognition celebrates a distinguished group of executives and organizations that are identified by an expert panel to be the nation’s trailblazers in the areas of health care diversity, equity, and inclusion.

These industry leaders influence policy and care delivery models across the country, while also nurturing and enhancing health care’s diversity and equity standards.

The 2022 individual awardees include leaders from health care institutions, education, and government.

“Since the day she arrived at AHN, Dr. Larkins-Pettigrew has been a remarkable advocate for diversity and health care equity, and she has had an extraordinary impact on the people and communities we serve in the Western Pennsylvania region,” said Cynthia Hundorfean, President and CEO, AHN. “Her inclusion on this list, for a second straight year, speaks not only to her own professional accomplishments, and the achievements of her team, but also to AHN and Highmark Health’s organizational progress toward creating a more equitable health care environment.”

Profiles of the Top Diversity Leaders will be published online at ModernHealthcare.com/top-diversity-leaders and in the Oct. 17 issue of Modern Healthcare magazine.

“The honorees on Modern Healthcare’s 2022 lists of Top Diversity Leaders and Organizations demonstrate a willingness to devote the resources necessary to execute meaningful diversity, equity and inclusion initiatives,” said Mary Ellen Podmolik, Modern Healthcare’s editor. “Their efforts to provide greater opportunities internally while advancing health equity initiatives in their communities set a great example for others to follow.”

At Highmark Health, Dr. Larkins-Pettigrew and the AHN Equitable Health Institute — which she established — are advancing a comprehensive internal and external strategy designed to promote a culture of equity and inclusion across every component of the health and wellness enterprise. That strategy includes evaluation of the organization’s recruitment, its employment and professional development practices, and the quality of care and services it provides to every patient and community.    

In 2021, Dr. Larkins-Pettigrew and her team focused their efforts on equitable COVID-19 vaccine distribution, ensuring that historically underserved communities and populations had equal access to the vaccine. In 2022, the Equitable Health Institute expanded its First Steps and Beyond program, a critical initiative established by AHN to reduce Black infant and fetal mortality and ensure that all babies born in the greater Pittsburgh region celebrate their first birthday.

Dr. Larkins-Pettigrew joined AHN in 2020 from University Hospitals/Case Western Reserve University School of Medicine in Cleveland, where she served as Professor of Obstetrics and Gynecology, Chair of Clinical Diversity and Inclusion and Assistant Dean of Students. She founded and continues to serve as CEO of the JustWondoor (Women and Neonates, Diversity, Outreach, Opportunity, Research) global health program; and in 2014, she was named the University’s Chair of Clinical Excellence and Diversity, an endowed position established to promote diversity of academic faculty.

Dr. Larkins-Pettigrew earned a bachelor’s degree in nursing at the University of Pittsburgh, a master’s degree in education from California State University, a master’s degree in public policy from the University of Pittsburgh and her medical degree from the University of Pittsburgh School of Medicine. She served in the U.S. Navy for 13 years, achieving the rank of lieutenant commander and completing an OBGYN internship at Portsmouth Naval Hospital.

She also completed a residency at Magee Women’s Hospital in Pittsburgh, and practiced at Magee for eight years, while also serving as Magee’s Director of Global Health Programs.

###

About the Allegheny Health Network:

Allegheny Health Network (AHN.org) is an integrated healthcare delivery system serving the greater Western Pennsylvania region. The Network is composed of 14 hospitals, ambulatory surgery centers, Health + Wellness Pavilions, an employed physician organization, home and community-based health services, a research institute, and a group purchasing organization. The Network provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, trauma care, cardiovascular disease, organ transplantation, cancer care, orthopedic surgery, neurology and neurosurgery, women’s health, diabetes, autoimmune disease and more. AHN employs approximately 21,000 people, has more than 2,600 physicians on its medical staff and serves as a clinical campus for Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.

About Highmark Health

Highmark Health, a Pittsburgh, PA-based enterprise that employs more than 37,000 people who serve millions of Americans across the country, is the parent company of Highmark Inc., Allegheny Health Network, enGen, Helion, and Lumevity. Highmark Inc. and its subsidiaries and affiliates provide health insurance to approximately 6.8 million members in Pennsylvania, West Virginia, Delaware, and New York, as well as dental insurance and related health products through a national network of diversified businesses. Allegheny Health Network is an integrated delivery network in western Pennsylvania comprised of 14 hospitals, more than 2,600 affiliated physicians, ambulatory surgery centers, an employed physician organization, home and community-based health services, a research institute, a group purchasing organization, and health and wellness pavilions. enGen’s dynamic ecosystem of smart automation and technology supports and streamlines complex operations for health plans and their provider partners. Helion works with payers to cultivate high-performing networks while empowering providers to operate at their best. Lumevity helps companies transform in ways that drive direct financial benefits while improving quality and increasing employee engagement. To learn more, visit http://www.highmarkhealth.org.

ClarisHealth Hires Tate McDaniel as Chief Revenue Officer


I’m excited to join ClarisHealth and have the opportunity to contribute to the mission of leveraging enterprise technology to empower health plans to realize the full potential of their payment integrity operations and remove the waste from healthcare.

ClarisHealth, provider of the industry’s leading payment integrity platform for health plans, today announced that Tate McDaniel joined the company’s senior leadership team as the chief revenue officer. McDaniel will lead the company’s integrated growth team to scale adoption of ClarisHealth’s enterprise payment integrity technology Pareo® in the payer market.

McDaniel brings to ClarisHealth over 20 years of industry experience managing enterprise growth initiatives, strategic partnerships, and consultative sales strategies targeting payers, providers, and self-insured employers.

“Tate possesses the right knowledge, tenacity, strategic acumen, and relationships to work with payers to unlock their full potential value enabled by enterprise payment integrity technology,” says ClarisHealth CEO Jeff McNeese. “I look forward to all we will accomplish together.”

McDaniel joins ClarisHealth having most recently served as SVP of Growth at IVX Health where he led provider sales, payer strategy and network contracting, and marketing in support of IVX’s expansion from eight to over 60 infusion centers nationally. Prior to IVX, he served as SVP and General Manager of Change Healthcare’s engagement solutions business working with dozens of health plans on strategic cost transparency and member engagement technology solutions.

“I’m excited to join ClarisHealth and have the opportunity to contribute to the mission of leveraging enterprise technology to empower health plans to realize the full potential of their payment integrity operations and remove the waste from healthcare,” says McDaniel. “I look forward to sharing the power of the Pareo platform with payers across the country.”

McDaniel holds a BBA in Finance from The University of Georgia and an MBA in Finance from Vanderbilt University – Owen Graduate School of Management. He lives in the greater Nashville, Tenn., area with his family.

About ClarisHealth

ClarisHealth, an Inc. 5000 and Deloitte Technology Fast 500 company and recognized for prospective payment integrity solutions in the Gartner Hype Cycle, is the answer to the health plan industry’s siloed solutions and traditional models for identification and overpayment recovery services. ClarisHealth provides health plans and payers with total visibility into payment integrity operations through its proprietary, A.I.-powered cost containment technology platform Pareo®. Pareo enables health plans to maximize cost avoidance and recoveries at the most optimized cost for a 15x return on their software investment.

Share article on social media or email:

Leaders celebrate topping out of UT Health San Antonio Multispecialty and Research Hospital


“This will be a hospital worthy of The University of Texas name.” — William L. Henrich, MD, MACP, president of The University of Texas Health Science Center at San Antonio

Surgeries in multiple specialties, new services for the region including stem cell therapies and bone marrow transplants, and access to the latest clinical research trials are drawing closer to reality as construction of the half-a-billion-dollar UT Health San Antonio Multispecialty and Research Hospital reaches an important milestone in the South Texas Medical Center.

Leaders of The University of Texas Health Science Center at San Antonio (UT Health San Antonio), community supporters and general contractor Vaughn Construction celebrated the hospital’s topping out and beam-signing ceremony today. Construction crews have reached the highest point of the eight-story project located at Ewing Halsell Drive and Wurzbach Road.

“Admitting hospital patients who are part of clinical research efforts is not done in our community now,” said William L. Henrich, MD, MACP, president of The University of Texas Health Science Center at San Antonio (UT Health San Antonio). “This will be a unique aspect of the truly comprehensive care our hospital provides for the region and will maximize patients’ opportunity for healing and recovery. The focus, the ultimate objective, is improved patient outcomes.”

The eight-story, 144-bed hospital will be patient- and family-focused. “We look forward to creating a uniquely different atmosphere for patients and their families, and also for providers and trainees who will usher in the next generation of health care in South Texas,” said Jeff Flowers, MBA, inaugural chief executive officer for the UT Health San Antonio Multispecialty and Research Hospital.

Integral to the design of the hospital is the healing environment with great attention to the patient and family experience. Walking trails that connect around the hospital will help patients and care supporters with stress release. Relaxation and respite areas will include amenities such as shower facilities where family members may freshen up. Patients will have dining options with room service-style menu offerings.

“Everything is designed to promote the healing process and help people build up their strength and feel good about their recovery and their experience,” Flowers said. “Natural light throughout the facility will create the right healing environment, as well, while features such as touchless technology will promote infection control.”

The hospital will include 12 specialized operating rooms, full imaging capabilities including MRI and CT, laboratory facilities, a blood bank and stem cell lab. The hospital design is 448,819 gross square feet and includes a 673-car parking garage and 200-car surface parking lot. A skybridge will connect the hospital to the Mays Cancer Center, the National Cancer Institute-Designated Cancer Center at UT Health San Antonio.

“This will be a world-class facility with technology and ambience backing up superb medical teams,” Henrich said. “This will be the predominant location of our adult oncology services and, as the name signals, other surgical specialties and clinical research. Here we will create a culture that is caring and passionate about taking care of the patient. This will be a hospital worthy of The University of Texas name.”

“President Henrich’s leadership has been integral to the development of this innovative, first-of-its-kind facility in San Antonio,” said John M. Zerwas, MD, executive vice chancellor for health affairs with The University of Texas System. “The compelling vision he put forward to local leaders yielded the outpouring of support necessary to make this project possible and has earned the community partnerships required to maintain this inpatient environment moving forward.”

In November 2019, the Board of Regents approved $80 million in Permanent University Fund Bond Proceeds for the project. The hospital is included in the UT System’s Capital Improvement Program.

“This hospital will offer a superior patient experience that enables advanced and personalized treatment for complex conditions,” said Robert A. Hromas, MD, FACP, dean of the Joe R. and Teresa Lozano Long School of Medicine and vice president for medical affairs at UT Health San Antonio. “Patients and their families will benefit from care provided right here in San Antonio rather than having to spend days or weeks far from home.”

Dignitaries signed a ceremonial beam and celebrated the construction progress during today’s event. The UT Health San Antonio Multispecialty and Research Hospital, a substantial boost to the city’s economy by adding more than 800 health care jobs, is projected to open in the late fall of 2024.

See also the website, https://uthealthsahospital.org/, including the “For the Media” tab with downloadable photos/videos, renderings and logos: https://uthealthsahospital.org/for-the-media/.

The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver for San Antonio’s $42.4 billion health care and biosciences sector, is the largest research university in South Texas with an annual research portfolio of $350 million. Driving substantial economic impact with its five professional schools, a diverse workforce of more than 7,000, an annual operating budget of more than $1 billion and a clinical practice that provides more than 2 million patient visits each year, UT Health San Antonio plans to add more than 1,500 higher-wage jobs over the next five years to serve San Antonio, Bexar County and South Texas. To learn about the many ways “We make lives better®,” visit https://uthscsa.edu.

Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.

Share article on social media or email:



FDA Awards Kemp Proteins Contract to Develop Monoclonal Antibodies for SARS-CoV-2 and Influenza Vaccine Potency Assays


Kemp Proteins announced today that it had been selected by the United States Food and Drug Administration (FDA) to develop monoclonal antibodies to SARS-CoV-2 and Influenza molecules. The FDA’s Laboratory of DNA Viruses (FDA/LDV) will use the antibodies developed by Kemp Proteins in the design of in-vitro assays for potency release of SARS-CoV-2 and Influenza vaccines.

Specifically for SARS-CoV-2 virus, there is a need for a deeper understanding of how the human body mounts an immune response to the virus. FDA/LDV is interested in developing monoclonal antibodies against the Spike protein receptor-binding domain for binding and competition assays that will use immune sera. Kemp Proteins will apply its custom antibody development technology to generate type-specific antibodies for SARS-CoV-2 targets for the FDA. Michael Keefe, CEO of Kemp Proteins, said “we are excited to have been selected and to be working with the FDA, to develop these important antibodies. We are looking forward to growing this working relationship with the FDA’s Laboratory of DNA Viruses.”

Additional to potency release assays, the FDA/LDV is investigating in-vitro binding and competition assays to evaluate the immune response to SARS-CoV-2 and influenza vaccines. Current influenza vaccine potency assays require a strain-specific antigen standard and a strain-specific antibody standard. These standards are made for each new strain included in the annual vaccines. The FDA will streamline the process by developing monoclonal antibodies that are type-specific rather than strain specific, so they can be more broadly used to assay the potency of all vaccine strains for influenza subtype.

About the Contract

The contract 75F40122P00547 “Monoclonal Antibody Production” is 100% supported with federal funds provided by the United States Food and Drug Administration (FDA). The content of this press release does not necessarily reflect the views or policies of the FDA, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

About Kemp Proteins (http://www.kempproteins.com)

Kemp Proteins LLC, a Six.02 Bioservices member company, is a leading provider of gene-to-protein, hybridoma, and cell line development services. Kemp’s team of experienced protein problem-solvers deliver best-in-class services that optimize productivity and mitigate risk for life sciences innovators developing protein-based products, including human and veterinary diagnostics, biopharmaceuticals, and vaccines. Kemp Proteins operates under a Quality Management System certified against ISO9001:2015 and ISO 13485:2016 standards.

Share article on social media or email:

Icahn School of Medicine at Mount Sinai Receives National Institutes of Health Award to Accelerate Development of New Treatments


“This grant enables us to keep pace with that growth and better serve our patients by raising the bar for the research we conduct and the care we provide.” – Rosalind J. Wright, MD, MPH

The Icahn School of Medicine at Mount Sinai has been awarded a five-year, $55.5 million grant from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) Program that will benefit the diverse patient population Mount Sinai serves by accelerating the development of new treatments for leading health conditions, including cardiorespiratory and psychiatric disorders, diabetes, malignancies, and infectious diseases. In particular, this award will be critical to support Mount Sinai’s ongoing response to emerging priorities such as the initial and longer term management of COVID-19.

The grant will support the work of ConduITS, the Institute for Translational Sciences at the Icahn School of Medicine at Mount Sinai, which is one of 63 sites nationwide in the Clinical Translational Science Award (CTSA) Program. Founded in 2009, ConduITS is dedicated to launching clinical studies quickly; enhancing collaborations with other CTSA Programs, community providers, patients, and industry; and promoting team science and effective methods for recruitment and retention of clinical research participants.

This is the third clinical and translational science award that ConduITS has received since 2009. The grant will enable the Mount Sinai Health System to harness its unique strengths in translational research informatics, digital health, and data science to accelerate the translation of research into discoveries that lead to better health outcomes for a diverse patient population across the lifespan. In particular, it will enable ConduITs to evolve its approach to precision medicine to include a precision public health framework that integrates genomics with key public health domains such as environmental health, social determinants of health, and big-data science to address health equity challenges.

“This grant confirms that Mount Sinai is a leader in clinical translational science nationwide. Many CTSA Programs at other leading health systems across the United States leverage unique aspects of our site, such as high performance computing, research informatics, and our exposomics infrastructure, which is beneficial for us and for the entire network,” says Rosalind J. Wright, MD, MPH, Director of ConduITS, the Horace W. Goldsmith Professor of Pediatrics at Mount Sinai Kravis Children’s Hospital, and Dean for Translational Biomedical Sciences at Icahn Mount Sinai.

“With this grant, we will be able to expand that infrastructure to, for example, continue building our integrated informatics ecosystem to facilitate big-data science across the network and enhance accessibility to data streams needed for researchers who are tackling society’s most pressing and complex health-related challenges such as health inequities, thus creating the potential to improve outcomes for all across our diverse patient populations. In this way the grant, and the science that it will facilitate, ultimately has the potential to be highly impactful in the delivery of health care. This infrastructure proved to be critical during the COVID-19 pandemic and enabled the rapid understanding of this new disease and the development of new vaccines and treatments.”

The time frame for development of new treatments is typically lengthy, between 10 to 15 years from initial scientific discovery to market launch. ConduITS will use the grant to continue to accelerate that development process and transform the local, regional, and national translational research network by:


  • Expanding programs that promote workforce diversity, with an emphasis on underrepresented racial and ethnic groups, and individuals with disabilities or from disadvantaged backgrounds.
  • Fostering transdisciplinary learning and team science to encourage innovation through collaborations and analysis across medical disciplines, including emerging fields such as precision medicine, exposomics, and public health.
  • Engaging a wide range of translational research stakeholders locally and nationally, including CTSA Programs, biotech and pharmaceutical companies, and most critically, patients.
  • Incorporating translational research, with a particular focus on perinatal and pediatric research, geriatric populations, and populations impacted by health disparities.

“Mount Sinai serves one of the biggest and most diverse patient populations in the world, and our footprint as a health system has grown significantly,” Dr. Wright says. “This grant enables us to keep pace with that growth and better serve our patients by raising the bar for the research we conduct and the care we provide. By sharing the discoveries and infrastructure made possible by the grant, we can further support the entire CTSA Program in achieving the same goals, enabling our field to better address the healthcare challenges we, and our patients, are facing.”

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight-member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.

Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 34 academic departments and 35 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.

Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with a current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai’s discoveries and innovations translate into healthcare products and services that benefit the public.

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.

Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

——————————————————-

  • Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

Leading Healthcare Providers Address Healthcare Inequities In Communities Of Color During Panel Hosted By Metro Edge Development Partners And Ilinois Medical District


IMD x Metro Edge Healthcare Panel Invitation

As we are aware, health inequities create a systematic difference in health outcomes. All of these CEOs have successfully led their organizations amidst a pandemic, some serving the most vulnerable populations in our city.

Metro Edge Development Partners, a commercial real estate development firm and minority business enterprise (MBE), is partnering with the Illinois Medical District to host a panel discussion moderated by Allyson Hansen, CEO & Executive Director of the Illinois Medical District Commission, on the healthcare inequities in communities of color. The panel will comprise Dr. Omar Lateef, President and CEO of Rush University Medical Center, Dr. Ngozi Ezike, President and CEO of Sinai Chicago, and Israel Rocha, CEO of Cook County Health.

The panel discussion, “An Inside Look At Healthcare Inequities In Communities Of Color,” will be held on Thursday, October 27th, from 4:00-6:00 pm CDT at the Chicago Center for Arts & Technology located at 1701 West 13th Street. To register for this free event, please visit medp.io/new-events.

“As we are aware, health inequities create a systematic difference in health outcomes. All of these CEOs have successfully led their organizations amidst a pandemic, some serving the most vulnerable populations in our city,” said Craig Huffman, CEO of Metro Edge. “We chose to host this panel to hear the perspectives of these leaders and expand the discussion around racial health disparities. Social Impact is in the DNA of Metro Edge and this is only the beginning.”

Metro Edge recently announced that the company secured a 75-year ground lease on a 1.97-acre parcel in the Illinois Medical District to build and operate a 21 megawatt, 184,750 square foot high-performance data center that will address the technology infrastructure needs of local and regional healthcare firms. The facility is expected to break ground in early 2023, having already secured 50% preleasing, with an opening estimated for 2024.

“COVID-19 further exposed the lack of access to quality health care in communities of color,” said Hansen. “I am pleased to moderate this panel and continue the conversation with these incredible innovators reshaping a path forward in the healthcare industry.”

###

About Metro Edge Development Partners

Metro Edge Development Partners is a Chicago-based commercial real estate development firm and minority business enterprise (MBE). Our mission is to pursue institutional-quality investment opportunities that deliver exceptional results to our financial and community partners. Led by a team with decades of private equity real estate experience, Metro Edge targets data centers, life sciences, and technology-oriented developments in primary urban locations around the country. Simply put, we create significant value in areas overlooked by our competitors. To learn more, please visit https://medp.io

Share article on social media or email:

Santa Clara Family Health Plan announces the launch of its Children’s Vaccination Readiness Initiative with distribution of children’s book to fight vaccine hesitancy


“Convenience and equity were top of mind when developing this new vaccination clinic. By employing grassroots strategies, we hope to reach busy families with small children and help alleviate the stress of making this important decision to protect their families against COVID-19.”

Santa Clara Family Health Plan will partner with local community-based organizations and public libraries to distribute Lily the Llama Helps Her Herd, a children’s book written by Stanford graduate Emma Rashes to promote COVID-19 vaccines for children.

Rashes’ debut book is dedicated to teaching young people and their families about the importance of vaccinations for themselves, and for the community.

“It is important for families with young children to have access to information about how vaccines work and why they are important,” Rashes says. “I hope that children and their families read Lily the Llama Helps Her Herd and feel empowered to make an informed decision to get vaccinated.”

SCFHP has purchased 2,300 copies of Lily the Llama Helps Her Herd to be distributed at seven San Jose Public Library locations, schools, Family Resource Centers, and other community-based organizations. Along with the book distribution, SCFHP will leverage the vaccine educational workshop Rashes developed with her Stanford mentors and roll out a communications toolkit to equip these organizations in having important vaccine conversations. To participate and get copies of the book, organizations should complete the survey found at http://www.surveymonkey.com/r/SCFHPLilytheLlama.

The SCFHP Blanca Alvarado Community Resource Center (CRC) is also offering a series of vaccination clinics open exclusively to infants and toddlers. During these targeted vaccine clinics, the CRC transforms into a welcoming space for children with games and friendly staff available to answer questions to make getting vaccines a positive experience.

“Convenience and equity were top of mind when developing this new vaccination clinic,” said Mike Gonzalez, SCFHP Director of Community Engagement. “By employing grassroots strategies, we hope to reach busy families with small children and help alleviate the stress of making this important decision to protect their families against COVID-19.”

Visit crc.scfhp.com to see the schedule for the SCFHP Blanca Alvarado CRC Infant and Toddler Vaccine Clinics. The Blanca Alvarado CRC is located at 408 N. Capitol Ave., San Jose, CA, 95133.

The Children’s Vaccination Readiness Initiative is in response to low vaccine rates amongst high-risk population groups. With the launch of the initiative, SCFHP seeks to use a targeted grassroots approach to engage and inform Medi-Cal beneficiaries aged 0-12 and their parents or caregivers about the importance of vaccinations, support families and providers in having safe and healthy conversations about immunizations and provide a calm vaccination experience.

“The pandemic has affected many families throughout the county and in our city. By partnering with the Santa Clara Family Health Plan, we hope to provide families’ access to health resources and information in ways that the whole family may enjoy and learn from,” said Jill Bourne, San José City Librarian.

Getting vaccinated and boosted for COVID-19 remains the best way to protect yourself, your family, and the community from catching and spreading COVID-19. According to data from the Centers for Disease Control and Prevention (CDC), unvaccinated individuals are at much higher risk for testing positive for COVID than those who are vaccinated.

About Santa Clara Family Health Plan

Santa Clara Family Health Plan (SCFHP) is a local, community-based health plan dedicated to creating opportunities for better health and wellness for all. In partnership with providers and community organizations since 1997, we work to ensure everyone in Santa Clara County has access to equitable, high-quality health care. With a strong commitment to integrity, outstanding service, and support for our community, we serve more than 315,000 people through our Medi-Cal and Cal MediConnect health care plans. For more information, visit

http://www.scfhp.com.

About the author

Emma Rashes is a recent Stanford University graduate. She hopes to pursue a career in medicine. This project emerged out of her passion for early childhood literacy and deep commitment to science education. She is grateful for the support and guidance from mentors at the Stanford Center for Health Education, Stanford Graduate School of Education, Stanford Biology Department, and Lucile Packard Children’s Hospital Stanford on this project. A lesson plan for Lily the Llama, which includes a link to a free eBook, can be found here.

###

Share article on social media or email: